Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients

S. Schneegans, L. Lück, K. Besler, L. Bluhm, JC. Stadler, J. Staub, R. Greinert, B. Volkmer, M. Kubista, C. Gebhardt, A. Sartori, D. Irwin, E. Serkkola, T. Af Hällström, E. Lianidou, M. Sprenger-Haussels, M. Hussong, P. Mohr, SW. Schneider, J....

. 2020 ; 14 (5) : 1001-1015. [pub] 20200404

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21020599

The combination of liquid biomarkers from a single blood tube can provide more comprehensive information on tumor development and progression in cancer patients compared to single analysis. Here, we evaluated whether a combined analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and circulating cell-free microRNA (miRNA) in total plasma and extracellular vesicles (EV) from the same blood sample is feasible and how the results are influenced by the choice of different blood tubes. Peripheral blood from 20 stage IV melanoma patients and five healthy donors (HD) was collected in EDTA, Streck, and Transfix tubes. Peripheral blood mononuclear cell fraction was used for CTC analysis, whereas plasma and EV fractions were used for ctDNA mutation and miRNA analysis. Mutations in cell-free circulating DNA were detected in 67% of patients, with no significant difference between the tubes. CTC was detected in only EDTA blood and only in 15% of patients. miRNA NGS (next-generation sequencing) results were highly influenced by the collection tubes and could only be performed from EDTA and Streck tubes due to hemolysis in Transfix tubes. No overlap of significantly differentially expressed miRNA (patients versus HD) could be found between the tubes in total plasma, whereas eight miRNA were commonly differentially regulated in the EV fraction. In summary, high-quality CTCs, ctDNA, and miRNA data from a single blood tube can be obtained. However, the choice of blood collection tubes is a critical pre-analytical variable.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020599
003      
CZ-PrNML
005      
20220412134112.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/1878-0261.12669 $2 doi
035    __
$a (PubMed)32246814
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Schneegans, Svenja $u Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
245    10
$a Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients / $c S. Schneegans, L. Lück, K. Besler, L. Bluhm, JC. Stadler, J. Staub, R. Greinert, B. Volkmer, M. Kubista, C. Gebhardt, A. Sartori, D. Irwin, E. Serkkola, T. Af Hällström, E. Lianidou, M. Sprenger-Haussels, M. Hussong, P. Mohr, SW. Schneider, J. Shaffer, K. Pantel, H. Wikman
520    9_
$a The combination of liquid biomarkers from a single blood tube can provide more comprehensive information on tumor development and progression in cancer patients compared to single analysis. Here, we evaluated whether a combined analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and circulating cell-free microRNA (miRNA) in total plasma and extracellular vesicles (EV) from the same blood sample is feasible and how the results are influenced by the choice of different blood tubes. Peripheral blood from 20 stage IV melanoma patients and five healthy donors (HD) was collected in EDTA, Streck, and Transfix tubes. Peripheral blood mononuclear cell fraction was used for CTC analysis, whereas plasma and EV fractions were used for ctDNA mutation and miRNA analysis. Mutations in cell-free circulating DNA were detected in 67% of patients, with no significant difference between the tubes. CTC was detected in only EDTA blood and only in 15% of patients. miRNA NGS (next-generation sequencing) results were highly influenced by the collection tubes and could only be performed from EDTA and Streck tubes due to hemolysis in Transfix tubes. No overlap of significantly differentially expressed miRNA (patients versus HD) could be found between the tubes in total plasma, whereas eight miRNA were commonly differentially regulated in the EV fraction. In summary, high-quality CTCs, ctDNA, and miRNA data from a single blood tube can be obtained. However, the choice of blood collection tubes is a critical pre-analytical variable.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x krev $x genetika $7 D014408
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cirkulující nádorová DNA $x krev $7 D000074141
650    _2
$a extracelulární vezikuly $x genetika $x metabolismus $x ultrastruktura $7 D000067128
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a tekutá biopsie $x přístrojové vybavení $x metody $7 D000073890
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x krev $x patologie $7 D008545
650    _2
$a mikro RNA $x krev $x genetika $7 D035683
650    _2
$a transmisní elektronová mikroskopie $7 D046529
650    _2
$a mutace $7 D009154
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádorové cirkulující buňky $x metabolismus $7 D009360
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lück, Lelia $u Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
700    1_
$a Besler, Katharina $u Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
700    1_
$a Bluhm, Leonie $u Centre of Dermatology, Elbe Clinics, Buxtehude, Germany
700    1_
$a Stadler, Julia-Christina $u Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany $u Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Germany
700    1_
$a Staub, Janina $u Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Germany
700    1_
$a Greinert, Rüdiger $u Centre of Dermatology, Elbe Clinics, Buxtehude, Germany
700    1_
$a Volkmer, Beate $u Centre of Dermatology, Elbe Clinics, Buxtehude, Germany
700    1_
$a Kubista, Mikael $u TATAA Biocenter AB, Gothenburg, Sweden $u Department of Gene Expression, Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic
700    1_
$a Gebhardt, Christoffer $u Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Germany
700    1_
$a Sartori, Alexander $u Agena Bioscience GmbH, Hamburg, Germany
700    1_
$a Irwin, Darryl $u Agena Bioscience GmbH, Hamburg, Germany
700    1_
$a Serkkola, Elina $u Orion Pharma, Orion Corporation, Espoo, Finland
700    1_
$a Af Hällström, Taija $u Orion Pharma, Orion Corporation, Espoo, Finland
700    1_
$a Lianidou, Evi $u Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, Department of Chemistry, University of Athens, Greece
700    1_
$a Sprenger-Haussels, Markus $u QIAGEN Inc/GmbH, Frederick, MD, USA $u QIAGEN Inc/GmbH, Hilden, Germany
700    1_
$a Hussong, Melanie $u QIAGEN Inc/GmbH, Frederick, MD, USA $u QIAGEN Inc/GmbH, Hilden, Germany
700    1_
$a Mohr, Peter $u Centre of Dermatology, Elbe Clinics, Buxtehude, Germany
700    1_
$a Schneider, Stefan W $u Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Germany
700    1_
$a Shaffer, Jonathan $u QIAGEN Inc/GmbH, Frederick, MD, USA $u QIAGEN Inc/GmbH, Hilden, Germany
700    1_
$a Pantel, Klaus, $u Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany $d 1960- $7 mub2013787219
700    1_
$a Wikman, Harriet $u Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 14, č. 5 (2020), s. 1001-1015
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32246814 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20220412134108 $b ABA008
999    __
$a ok $b bmc $g 1691220 $s 1141045
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 14 $c 5 $d 1001-1015 $e 20200404 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options